Agenus Inc. filings document the regulatory record for a clinical-stage immuno-oncology company developing antibody-based cancer therapies, led by the BOT+BAL program of botensilimab and balstilimab. Its Form 8-K reports cover periodic financial results, clinical-program and access-program updates, material agreements, securities-related amendments and the completed disposition of manufacturing assets with related license arrangements.
Proxy and governance filings describe board matters, executive compensation, shareholder voting items and equity awards. Other event reports document officer appointments, capital-structure changes, unregistered securities activity and legal or regulatory matters affecting the company's public-company disclosures.
BlackRock, Inc. reports beneficial ownership of common stock of AGENUS INC. BlackRock and certain of its subsidiaries collectively beneficially own 2,513,893 shares, representing 6.0% of Agenus’s common stock outstanding.
BlackRock has sole voting power over 2,485,590 shares and sole dispositive power over 2,513,893 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Agenus’s outstanding common shares.
RA Capital Management, L.P. and related reporting persons report beneficial ownership of up to 4,344,772 shares of Agenus Inc. common stock, representing 9.99% of the class, based on recent outstanding share data and warrant exercisability. This position is held through RA Capital Healthcare Fund, L.P., which directly owns 4,122,000 shares and holds multiple series of warrants for additional shares. Contractual Beneficial Ownership Blockers in the warrants prevent exercises that would push ownership above 9.99% of outstanding common stock. The reporting persons, who expressly disclaim status as a group and certain aspects of beneficial ownership outside Section 13(d) of the Exchange Act, share voting and dispositive power over the reported shares and warrants.
Agenus Inc., a clinical-stage immuno-oncology company, has filed a resale registration covering up to 2,133,333 shares of common stock previously issued to Zynext Ventures USA LLC under a June 2025 Securities Purchase Agreement. The shares were originally sold in a private strategic investment at $7.50 per share for an aggregate purchase price of approximately $16.0 million, with the transaction closing on January 15, 2026.
The registration allows the holder and its permitted transferees to resell these shares over time, but does not require any sales. Agenus will bear registration expenses and will not receive any proceeds from any resale of these shares. As of July 17, 2026, common shares outstanding were 44,752,288. The company focuses on antibody-based cancer immunotherapies, led by botensilimab and balstilimab, and holds a $24.3 million equity stake in MiNK Therapeutics plus a majority interest in vaccine adjuvant subsidiary SaponiQx.
Research and development expenses were $79.3 million in 2025 and $11.8 million for the quarter ended March 31, 2026. Agenus has incurred substantial cumulative losses, with an accumulated deficit of $2.18 billion as of December 31, 2025. Its auditor’s report includes an explanatory paragraph stating that recurring losses and net capital deficiency raise substantial doubt about the company’s ability to continue as a going concern.
Agenus Inc. has a large shareholder group led by Invus Public Equities, Avicenna Life Sci Master Fund, related entities, and Raymond Debbane reporting their holdings of common stock and warrants. As of July 13, 2026 they collectively beneficially owned 4,533,755 shares of common stock, combining 2,419,263 outstanding shares and 2,114,492 shares issuable upon exercise of warrants, representing 9.99% of Agenus’s outstanding common stock. This calculation is based on 41,642,431 shares outstanding as of May 7, 2026, plus 1,626,015 shares issued in a July 15, 2026 private placement and the 2,114,492 shares issuable under the warrants. The filing states these securities are not held for the purpose of changing or influencing control, and all warrants are subject to a 9.99% Beneficial Ownership Limitation on exercise.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Garo H. Armen received 4,852 shares of common stock on July 10, 2026 as a grant in lieu of cash salary. The shares represent the net amount of his salary for that pay period, are issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan, and are fully vested on the date of issuance. The share amount is based on the $3.35 closing price of Agenus common stock on July 10, 2026. Following this award, Armen holds 371,108 shares directly, plus additional indirect holdings through IRA accounts and trust and partnership entities.
Agenus Inc. entered into a securities purchase agreement for a private placement expected to close on July 15, 2026. The company will issue and sell 23,035,227 shares of common stock (or equivalent pre-funded warrants), Series A warrants for 21,144,277 shares at an exercise price of $4.02, and Series B warrants for 33,797,214 shares at $5.03. The combined effective purchase price per share plus accompanying warrants is $3.69, providing approximately $85 million in upfront gross proceeds and up to an additional $255 million upon full warrant exercise, for total potential gross proceeds of up to $340 million.
The financing supports a strategic prioritization of the botensilimab and balstilimab (BOT+BAL) regimen for neoadjuvant treatment of microsatellite-stable colon cancer, including the planned 850-patient Phase 3 ROBBIN trial with event-free survival as the primary endpoint. Agenus plans to discontinue financial support for the BATTMAN Phase 3 metastatic study. Based on current plans, existing cash plus net proceeds are expected to fund operations into the third quarter of 2027 without warrant exercise and through year-end 2031 if all Series A and B warrants are fully exercised. The company also agreed to add two Commodore Capital–designated directors as part of expanding its board to nine members and entered into a registration rights agreement to register resale of the shares and warrant shares.
AGENUS INC director Thomas L. Harrison received a grant of 8,547 shares of common stock on July 1, 2026. These shares were acquired under the company’s Board Compensation Election Policy, where directors can take their fees in stock. At a reference price of $3.583 per share, his direct holdings increased to 47,545 shares.
AGENUS INC director Timothy Wright reported a routine compensation grant of Deferred Stock Units. On July 1, 2026, he acquired 2,267.765 Deferred Stock Units, each tied to the company’s common stock on a 1-for-1 basis under the directors’ deferred compensation plan.
The units were valued at $3.583 per Deferred Stock Unit, based on the average closing price of the company’s stock during the prior calendar quarter. Following this award, Wright holds a total of 26,180.771 Deferred Stock Units, which are typically settled in common shares after he ceases serving as a director.
Agenus Inc. entered into an agreement with existing noteholders that extends the maturity of $5.09 million of senior subordinated promissory notes from June 20, 2026 to February 18, 2027, keeping all other note terms the same.
The company also extended to June 25, 2031 the expiration dates of three existing warrant series covering an aggregate 165,000 shares of common stock, all at an exercise price of $3.25 per share. In addition, Agenus issued new 2026 D Warrants to certain noteholders to purchase 56,525 shares at the same exercise price, also expiring on June 25, 2031. The shares issuable under the new D Warrants are expected to be registered for resale within 90 days after June 29, 2026.